|
Jul 15
|
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
|
|
Jun 30
|
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
|
|
Jun 25
|
OTC Markets Hosts Virtual Investor Presentation with Stacy Lindborg, President, CEO, and Board Director of Imunon, and David Bautz, PhD, Senior Analyst at Zacks SCR
|
|
Jun 20
|
IMNN: Translational Data from OVATION 2 Presented…
|
|
Jun 18
|
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
|
|
Jun 17
|
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
|
|
Jun 13
|
Life Sciences Investor Forum: Now Available for Online Viewing
|
|
Feb 10
|
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
|
|
Aug 28
|
IMUNON to Host R&D Day on September 18th
|
|
Aug 14
|
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
|
Aug 7
|
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
|
|
Jul 30
|
Top Midday Gainers
|
|
Jul 30
|
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
|
|
Jul 29
|
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
|
|
Jun 24
|
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
|
|
Feb 22
|
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
|
|
Dec 11
|
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 23
|
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
|
|
Oct 19
|
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
|
|
Oct 18
|
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
|